ESMO-BC 2024
May 15 - 17, 2024 | Berlin, Germany
The agents listed below are currently under investigation. Their safety and efficacy have not been established.
Poster
Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degrader, Plus Palbociclib in Estrogen Receptor+/Human Epidermal Growth Factor Receptor 2- Advanced Breast Cancer: Updated Phase 1b Cohort ResultsEP Hamilton et al.
Poster
TACTIVE-K: Phase 1b/2 Study of Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degrader, in Combination With PF-07220060, a Cyclin-Dependent Kinase 4 Inhibitor, in Estrogen Receptor+/Human Epidermal Growth Factor Receptor 2- Advanced Breast CancerML Telli et al.